Intravenous Solutions Market Size & Share 2026-2035

Intravenous Solutions Market Size

The intravenous solutions market size was valued at USD 14.8 billion in 2025 and is expected to reach USD 32.3 billion in 2035, growing at a CAGR of 8.2% from 2026 to 2035, according to the latest report published by Global Market Insights Inc.

Malnutrition around the world is on the rise, which is leading to more demand for intravenous solutions in emerging as well as developed markets. For instance, according to the data from the World Health Organization (WHO), malnutrition was a leading cause of an estimated 148.1 million children under 5 years of age experiencing stunted growth. Moreover, several factors, such as rising chronic diseases and food scarcity, further accelerate market growth.

The World Health Organization (WHO) further estimates that more than 3 billion people around the globe are not able to afford a healthy meal, which not only increases malnourishment but also shows the glaring need for better access to nutrition. In addition, the surging demand for IV solutions in neonatal and pediatric wards is mainly attributed to a large percentage of preterm births. Preterm birth, which happens prior to 37 weeks of gestation, remains a global challenge because it is associated with morbidity and mortality.
 

According to WHO, in 2020, there were 13.4 million preterm births worldwide, whereas preterm birth complications were the leading cause of deaths in children under five and accounted for around 900,000 lives in 2019. Further, the relative annual incidence is 4-16% across different countries. Thus, intravenous solutions, such as parenteral nutrition (PN), are necessary in providing essential nutrients as well as hydration to preterm infants, thereby promoting industry expansion. The top 5 players in this market are Baxter International, Fresenius Kabi, Kelun Industry Group, B. Braun Melsungen, and Otsuka Pharmaceutical.
 

Intravenous (IV) solutions, or IV fluids, are sterile liquids injected into a patient’s bloodstream via a vein. These solutions are employed to maintain a patient’s hydration, administer medications, and supply needed nutrients to patients that cannot ingest them or maintain electrolyte balance.

Intravenous Solutions Market Trends

• Healthcare providers prefer to use IV solutions which are customized and pre-mixed. These solutions eliminate the need for manual compounding, thereby reducing the risk of contamination and preparation errors. This trend is particularly evident as precision and safety are being emphasized while administering the IV solutions.
   
• The key players in the market are focusing on providing pre-mixed IV solutions to the end users in order to enhance their overall operational efficiency. For instance, Baxter's Clinimix is a premixed parenteral nutrition. With up to 80 grams of amino acids per liter, it is a ready-to-use nutritional solution.
   
• Moreover, home healthcare is observed as an advancing trend as patients are willing to have treatments in the comfort of their homes. Further, advances in infusion solutions and remote healthcare are supporting this shift.
   
• Furthermore, usage of multi-chamber bags (MCBs) is on the rise in home parenteral nutrition, and the methods of delivery of PN vary geographically, with compounded PN bags being favored in some areas and market-authorized multi-chamber bags (MCBs) in others.
   
• Another focus area for manufacturers is sustainable packaging, which involves the use of eco-friendly adhesives and recycled materials.
   
• For instance, Baxter's Cuernavaca site in Mexico has transitioned to water-based adhesives instead of solvent-based for cardboard shipping boxes used in distributing IV solutions and renal products (6L and Twin Bag). Such initiatives are anticipated to augment market growth.
   

Intravenous Solutions Market Analysis

Based on type, the market is segmented into total parenteral nutrition and peripheral parenteral nutrition. The peripheral parenteral nutrition segment dominated the market with the largest revenue of USD 8.9 billion in 2025.
 

• Peripheral parenteral nutrition (PPN) is a method that is commonly used for patients that are dependent on short-term nutritional aid, as it supplies vital components such as amino acids, dextrose, and lipids through peripheral veins.
   
• PPN can boost nutritional balance, prevent further nutrition loss, and rectify deficiencies that patients with limited oral intake or enteral nutrition struggle with by supplying micromolecules and macromolecules in appropriate measure.
   
• Studies show a positive correlation between patient satisfaction and timely PPN administration. For instance, a nutrition-focused report from the Journal of Parenteral and Enteral Nutrition states that patients on PPN have a lower chance of developing infection or metabolic problems than those that were not placed on nutritional support.
   
• In addition, there has been a greater incidence of cases that need temporary nutrition support, such as patients after gastrointestinal surgeries, patients with mild malabsorption syndromes, or patients with acute conditions. Therefore, the market is expected to grow in the forecast period owing to the aforementioned factors.
   

Based on composition, the intravenous solutions market is segmented into carbohydrates, vitamins and minerals, single-dose amino acids, parenteral lipid emulsion, and other compositions. The carbohydrates segment emerged as a dominant segment in the market, accounting for 40.7% of the revenue share in 2025.
 

• Carbohydrates primarily exist as dextrose, an essential part of an intravenous solution which serves as an energy reservoir for the patients that cannot receive nourishment orally or through an enteral method. IV solutions with dextrose have continually increased their market share as they are essential in providing carbohydrate energy deficits among critical care patients all over the world.
   
• Dextrose-based IV solutions provide necessary caloric support, preventing catabolism of lean body mass and ensuring adequate energy for cellular processes, particularly in malnourished or critically ill patients.
   
• Further clinical evidence supports that supplementation of carbohydrates is important for metabolic maintenance. For instance, research from ‘Critical Care Medicine’ reveals that the use of dextrose enriched IV therapy lowers the incidence of hypoglycaemia and aids recovery for postoperative and trauma patients.
   
• Also, programs like Enhanced Recovery After Surgery (ERAS) also appreciate the use of intravenous carbohydrate solutions with the surgery for better recovery of patients, thereby boosting demand for IV solutions.
   

Based on age group, the intravenous solutions market is segmented into pediatric, adults, and geriatric. The geriatric segment accounted for the largest revenue share of 48.8% in 2025.
 

• Geriatric patients are quite vulnerable to dehydration as their thirst sensation is lowered, they undergo certain mobility issues, or other health conditions, which makes rapid hydration a crucial factor. IV solutions offer an efficient way to deliver essential nutrients and fluids, which can cover the deficiencies that could otherwise worsen frailty or exacerbate chronic illnesses.
   
• Moreover, patients in this age group also face difficulty swallowing food, which results in poor appetite. They also deal with various gastrointestinal disorders, complicating nutrient absorption. IV solutions can eliminate these challenges by directly administering fluids, ensuring effective treatment.
   
• Further, an increasing geriatric population is expected to bolster this market in the forecast period. For instance, according to WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over. Moreover, the population of people aged 60 years and over is projected to double (2.1 billion) by 2050. Thus, the growing geriatric population boosts the requirement for IV solutions, thereby accelerating market growth.
   

Based on application, the intravenous solutions market is segmented into nutritional support, blood transfusion, fluid and electrolyte balance, and other applications. The nutritional support segment dominated the market, accounting for USD 6.6 billion in 2025.
 

• The leading position within this segment is attributed to the increased percentage of people suffering from malnutrition, chronic diseases, and patients recovering from surgery and needing parenteral nutrition.
   
• Treatment for malnutrition is a big issue on the global scale. WHO estimates that around 45 million children below the age of 5 are suffering from wasting (low weight-for-height), which is a severe stage of malnutrition. This has boosted the need for IV nutritional support in hospitals, ICUs, and pediatric units.
   
• Moreover, certain gastrointestinal disorders like Crohn’s disease, short bowel syndrome, and pancreatitis make it difficult to absorb nutrients, which increases the requirement for IV-administered nutrition.
   
• Furthermore, critically ill and post-operative patients are frequently facing severe malnutrition. These patients need parenteral nutrition if they want to recover fully.
   
• Moreover, IV-based nutritional support further escalates with the elderly population who are already malnourished and have difficulty feeding themselves.

Based on end use, the intravenous solutions market is segmented into hospitals and clinics, ambulatory surgery centers, and home care settings. The hospitals and clinics segment accounted for the largest share of 58.9% in 2025.
 

• Hospitals are the primary users of IV solutions since they are integral in fluid resuscitation, parenteral drug administration, electrolyte balance, and nutrition support for patients during surgeries, trauma, severe dehydration, and chronic illnesses.
   
• Clinics are adopting IV therapy for short-term treatments and daycare procedures for managing chronic diseases, contributing significantly to the growth of the market.
   
• The increasing occurrence of chronic diseases, such as cancer and kidney disease, as well as gastrointestinal disorders, is propelling the need for IV nutrition and hydration therapy in hospitals and specialized clinics.
   
• In addition, the market share for this segment is expected to be bolstered by strengthening healthcare infrastructure, rising rates of hospitalization, and further spending on updated IV formulations.

North America Intravenous Solutions Market

North America accounted for the largest share of the global intravenous solutions industry, driven by its advanced hospital infrastructure, high surgical procedure volume, and strong utilization of parenteral nutrition and fluid therapy across critical care, oncology, neonatal, and chronic disease management settings.
 

• The region benefits from widespread demand in hospitals, clinics, ambulatory centers, and rapidly expanding home healthcare services.
   
• A key competitive strength for North America is its well‑established regulatory ecosystem, led by the U.S. FDA and Health Canada, which enforce stringent sterility, labelling, quality control, and GMP compliance requirements. These systems ensure consistent product standards, patient safety, and robust oversight for IV fluids and parenteral nutrition solutions entering the market.
   
• The region’s dominance is reinforced by a substantial and growing burden of chronic and acute health conditions, including cancer, gastrointestinal disorders, neurological diseases, and high rates of hospital admissions, which significantly increase the use of IV hydration, electrolyte solutions, and nutritional support therapies.
   

The U.S. intravenous solutions market size reached USD 5.3 billion in 2025, growing from USD 5 billion in 2024.
 

• The high preterm birth rates in the U.S. are a significant contributor to the growth of this market. For instance, according to the statistics from the Centers for Disease Control and Prevention, in 2023, the preterm birth rate was 10.41%, similar to the rate of 10.38% in 2022.
   
• In addition to this, the U.S. Food and Drug Administration (FDA) has implemented rigorous standards for IV solutions, driving the development of high-quality products with enhanced safety, efficacy, and stability to meet the growing demand for effective treatments in hospitals and outpatient settings.
   

Europe Intravenous Solutions Market

The Europe market accounted for USD 4.1 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe held a strong and well‑established position in the global intravenous (IV) solutions market in 2025, supported by its mature hospital infrastructure, structured clinical pathways, and widespread availability of specialist care across EU member states. The region’s well‑organized healthcare systems and high standards of patient management drive consistent utilization of IV fluids, electrolyte solutions, and parenteral nutrition across acute, chronic, surgical, and intensive‑care settings.
   
• A major contributor to Europe’s sustained demand for IV solutions is the high prevalence of disease‑related malnutrition, which significantly increases the need for hydration therapy, electrolyte correction, and parenteral nutrition. According to WHO/Europe, disease‑related malnutrition affects 30–50% of hospitalized patients, particularly older adults and individuals with chronic diseases such as cancer or diabetes. This population‑level burden creates strong, ongoing clinical reliance on IV nutritional and fluid support across hospitals in the region.
   
• With ongoing advancements in IV therapy technology, expanding adoption of sterile, ready‑to‑use IV bags, and tighter regulatory oversight by agencies such as the EMA, Europe is expected to maintain a strong position in the global IV solutions market over the forecast period.
   

The intravenous solutions market in the UK is expected to experience significant and promising growth from 2026 to 2035.
 

• In the UK, the intravenous (IV) solutions market is expected to grow considerably, supported by rising utilization of IV therapies across oncology, acute care, and nutrition management. A major growth driver is the increasing volume of complex treatments such as chemotherapy and hospital-based nutritional interventions, both of which rely heavily on sterile IV fluids, electrolytes, and parenteral nutrition solutions.
   
• According to the House of Commons Library, 138,579 cancer deaths were recorded in England in 2022, reflecting a 9% increase since 2001. This growing cancer burden significantly amplifies the need for IV solutions across chemotherapy management, hydration therapy, symptom relief, and supportive care for advanced cancers. As the cancer population expands, demand for standardized, ready-to-use IV fluids in oncology units is expected to remain strong.
   
• Alongside oncology, increasing hospital admissions for chronic diseases and age-related conditions continue to expand the need for IV hydration and nutrition therapy. With a growing elderly population, rising comorbidities, and high rates of disease-related malnutrition in hospital settings, the UK healthcare system remains heavily dependent on IV solutions for acute, perioperative, and long-term care.
   

Asia Pacific Intravenous Solutions Market

The Asia-Pacific region is projected to show lucrative growth of about 8.8% CAGR during the forecast period.
 

• Asia‑Pacific is rapidly emerging as one of the fastest‑growing regions in the global intravenous (IV) solutions market, supported by its large and diverse population, expanding hospital capacity, and rising need for IV‑based hydration, medication delivery, and parenteral nutrition. The region spans advanced health systems such as Japan, South Korea, and Australia, alongside rapidly developing markets including China, India, and Southeast Asia, creating significant opportunities for IV solution adoption.
   
• South Asia’s escalating malnutrition crisis is significantly amplifying the region’s reliance on IV nutritional and hydration support. UNICEF reported in 2025 that South Asia carries the largest burden of undernutrition in the world, with 1 in 3 children under five stunted, 1 in 10 suffering from wasting, and 1 in 4 born with low birth weight.
   
• This “triple threat of malnutrition” places millions of children at risk and sharply increases demand for hospital‑based parenteral nutrition and IV hydration therapy, particularly in neonatal, pediatric, and emergency care units across the region.
   
• Building on its large population base, expanding healthcare access, and urgent need for improved nutrition and chronic disease management, Asia‑Pacific is expected to remain one of the fastest‑growing regions for IV solutions globally.
   

The Japan intravenous solutions market is anticipated to witness lucrative growth during the forecast period.
 

• Japan has observed an increasing burden of gastrointestinal disease, which is a reason promoting market growth in the forecast period. According to NCBI, since 1990, cancer has been a major contributor to gastrointestinal-related deaths in Japan. Although cancer-associated age-standardized mortality rates and DALYs are decreasing, crude rates have been increasing.
   
• Moreover, Japan has a massive aging society; according to Statista, by November 2023, around 36.35 million people in Japan were estimated to be over 65 years of age.
   
• Therefore, it is expected that an aging society will heavily affect the disease burden in Japan in the near future, and hence NCBI has estimated the gastrointestinal disease burden to rise by 2035, further fostering the IV solution market.
   

Latin America Intravenous Solutions Market

Brazil market is experiencing significant growth in the market.
 

• Brazil is experiencing significant growth in the intravenous (IV) solutions market, driven by its large population, expanding healthcare infrastructure, and rising demand for hydration, electrolyte management, medication delivery, and parenteral nutrition across public and private hospitals. The country has emerged as one of the most important and steadily expanding IV therapy markets in Latin America.
   
• Regulatory support from ANVISA and expanding local production capabilities have strengthened supply resilience and improved access to high-quality IV fluids. Collaboration with global manufacturers has enabled faster regulatory approvals, technology transfer for aseptic filling, and the establishment of advanced cleanroom facilities.
   
• With rising chronic disease burden, increasing surgical procedures, growing adoption of home-infusion services, and sustained investment in sterile manufacturing and hospital infrastructure, Brazil is positioned to grow IV solutions markets in Latin America.
   

Middle East and Africa Intravenous Solutions Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2026 to 2035.
 

• Saudi Arabia is witnessing a major demographic shift, with the population aged 60+ expected to increase five-fold, from 2 million (5.9% of the total population) in 2020 to 10.5 million by 2050.
   
• This rapid aging trend significantly elevates the country's long-term clinical need for IV hydration, electrolyte management, and parenteral nutrition, as older adults experience higher rates of dehydration, chronic diseases, post-operative recovery needs, and hospitalization episodes requiring IV therapy.
   
• Investment in modern healthcare infrastructure and specialized infusion services are also reshaping the market. In 2024, Riyadh saw the launch of IV ONE, the country’s first dedicated outpatient infusion therapy center, designed to support chronic illness management, nutrient deficiencies, and personalized IV treatment pathways, a model expected to boost adoption and accessibility of IV therapies.
   
• With rising geriatric demographics, expanding chronic disease incidence, stronger investment in healthcare infrastructure, and a shift toward preventive and outpatient IV therapy models, Saudi Arabia is poised for significant growth in the IV solutions market in the Middle East and Africa.
   

Intravenous Solutions Market Share

• The global intravenous solutions industry is highly competitive, characterized by a mix of long-established multinational manufacturers and rapidly expanding high-capacity producers. Market players are strengthening their competitive positions through large-scale sterile manufacturing, innovation in parenteral nutrition and electrolyte-balanced formulations, and integration of smart infusion systems that enhance dosing accuracy and patient safety.
   
• Leading companies such as Baxter International Inc., Fresenius Kabi AG, Kelun Industry Group, B. Braun Melsungen AG, and Otsuka Pharmaceutical Co., Ltd. collectively anchor the global IV solutions market. Recent industry developments further reinforce competitive momentum, especially through targeted capacity expansion. In October 2024, B. Braun announced a significant scale-up of IV fluid manufacturing, ramping up production at its Irvine (CA) and Daytona Beach (FL) facilities, with output expected to rise by 20% within 20 weeks. Additionally, digital health platforms and telemedicine services are also changing patient preferences, increasing the need for outpatient and home IV therapy, and enabling leading participants to enhance their share in the market.
   
• Overall, the competitive dynamics of the IV solutions market continue to be shaped by rising global healthcare needs, including increased surgical volumes, growing chronic disease burden, expanding elderly populations, and elevated requirements for parenteral nutrition across critical-care and inpatient settings.
   

Intravenous Solutions Market Companies

Some of the eminent market participants operating in the intravenous solutions industry include:

• Aculife Healthcare
• AdvaCare Pharma
• Albert David
• Amanta Healthcare
• Axa Parenterals
• B. Braun Melsungen
• Baxter International
• CSL
• Fresenius Kabi
• Grifols
• Haisco Pharmaceutical Group
• ICU Medical
• JW Life Science
• Kelun Industry Group
• Otsuka Pharmaceutical
   
• Kelun Industry Group

Kelun Industry Group is one of the world’s most influential and rapidly expanding manufacturers in the intravenous solutions market. The company’s leadership is built on its large-scale sterile manufacturing capabilities, broad formulation portfolio, and cost-efficient production of crystalloids, electrolyte solutions, and parenteral nutrition products. Kelun Industry Group’s growing international footprint, reinforced by its strong presence across Asia-Pacific, enables it to support global supply stability, meet rising hospital demand, and strengthen access to essential IV therapies worldwide.
 

• B. Braun Melsungen

B. Braun is a major global force in intravenous therapy and infusion technology, offering one of the industry’s most comprehensive portfolios of sterile IV fluids, parenteral nutrition solutions, and advanced infusion systems. The company continues to reinforce its competitive position through strategic production expansion and supply-chain resilience efforts.
 

• Otsuka Pharmaceutical

Otsuka is a significant global player in the intravenous solutions and clinical nutrition market, recognized for its strong capabilities in sterile manufacturing and its contributions to essential IV formulations used in hydration, nutrient delivery, and medication administration. Otsuka leverages its research-driven approach and extensive healthcare portfolio to support safe, reliable, and high-quality IV therapies across hospital and outpatient care settings.
 

Intravenous Solutions Industry News:

• In June 2024, Grifols S.A. announced that Biotest received FDA approval for Yimmugo, an intravenous immunoglobulin therapeutic for treating primary immunodeficiencies. This approval extended the company’s IV solutions portfolio and strengthened its market positioning.
   
• In November 2024, ICU Medical, Inc. partnered with Otsuka Pharmaceutical Factory to enhance supply chain resilience and innovation in North American IV solutions, leveraging OPF’s Asian manufacturing expertise and ICU Medical’s regional production and distribution capabilities to strengthen market position and meet rising healthcare demands.
   

The intravenous solutions market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Total parenteral nutrition
• Peripheral parenteral nutrition

Market, By Composition

• Carbohydrates
• Vitamins and minerals
• Single-dose amino acids
• Parenteral lipid emulsion
• Other compositions  

Market, By Age Group

• Pediatric
• Adults
• Geriatric

Market, By Application

• Nutritional support
• Blood transfusion 
• Fluid and electrolyte balance
• Other applications

Market, By End Use

• Hospitals and clinics
• Ambulatory surgery centers
• Home care settings

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE